Percutaneous coronary intervention (PCI) with stent placement is a standard treatment of obstructive coronary artery disease. Stent thrombosis (ST), although rare, is a devastating complication after PCI and results in significant morbidity and mortality. 1 The incidence of ST is estimated to be < 1% in randomized trials and most commonly occurs early, in the first 30 days after stent placement. 1, 2 Recently, the use of more potent antiplatelet therapy 3,4 and second-generation drug-eluting stents (DES) 2, 5 has been shown to reduce the incidence of ST. The aim of this study was to describe the incidence and the characteristics of patients who presented with ST-segment elevation myocardial infarction (STEMI) due to ST in contemporary real-world practice.
Methods Study Population
A single-center retrospective analysis was performed on 527 patients who presented with STEMI and underwent emergent coronary angiography and PCI from 2007 to 2014 at the Mount Sinai Beth Israel Hospital. All patients with STEMI who underwent emergency PCI were included in this study without exclusion. STEMI was diagnosed according to the American College of Cardiology and European Society of Cardiology criteria (i.e., chest pain persisting ! 30 minutes associated with ST-segment elevation ! 0.1 mV in ! 2 continuous electrocardiographic leads).
Abstract
Stent thrombosis (ST) is a rare but devastating complication after percutaneous coronary intervention. Newer generation drug-eluting stents (DES) and newer antiplatelet therapies have been shown to decrease the incidence of ST, but we continue to observe ST-segment elevation myocardial infarction (STEMI) due to ST in contemporary practice. A retrospective analysis of 527 patients who presented with STEMI was performed; 57 patients (11%) with angiographically confirmed ST were compared with the patients with STEMI due to de novo lesion. The type of previous stent, the timing of ST, and the use of antiplatelet therapy were reviewed in patients with ST. Patients with ST had higher prevalence of comorbid conditions, such as hypertension, diabetes mellitus, and coronary artery disease, and had lower left ventricular ejection fraction (37 AE 5 vs. 44 AE 16%, p ¼ 0.0011). There was no difference in in-hospital mortality (2 vs. 4%, p ¼ 0.7082). ST was seen most commonly as "very late" (56%), and with previous second-generation DES (40%). Eighty-two percent of patients among early ST, compared with 22% of patients with very late ST were on dual antiplatelet therapy (DAPT). In 12% of patients, ST happened after DAPT was stopped by physician for procedures. ST is seen in a variety of clinical settings with the most common presentation being very late ST and in second-generation DES, which most likely represent the growing population with previous second-generation stents.
Data Collection
A team of researchers independently reviewed the emergency department records, in-hospital admission records, and cardiac catheterization studies. The clinical characteristics of the patients were recorded into a database and included comorbid conditions such as hypertension, diabetes mellitus, dyslipidemia, and history of prior coronary artery disease requiring revascularization. Coronary angiography was reviewed by an experienced interventional cardiologist. ST was defined according to the Academic Research Consortium definition with angiographic confirmation of "definite" ST. The timing of ST was defined as "acute" (within 24 hours), "subacute" (within 1 month), "late" (within 1 year), and "very late" (after 1 year).
6 Angiographic and procedural characteristics such as culprit artery, thrombolysis in myocardial infarction (TIMI) flow grade, and multivessel involvement were also documented. In patients who presented with ST, information regarding the type of previous stent, timing of the event, and the use of and compliance with antiplatelet therapy were extracted from the medical record. Dual antiplatelet therapy (DAPT) was defined as the use of aspirin along with one of the P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor). In-hospital clinical events (death, recurrent myocardial infarction, target vessel revascularization) and peak cardiac enzymes were recorded as clinical outcomes.
Statistical Analysis
Clinical and procedural characteristics were compared between patients who presented with ST and those without ST. Continuous variables were compared using Student t-test. Categorical variables were compared using chi-square test or Fisher exact test. A p-value of less than 0.05 was regarded as statistically significant. The present study complied with the declaration of Helsinki and was approved by the Institutional Review Board of our institution.
Results
Among 527 patients with STEMI, 57 patients (11%) had angiographically confirmed stent thrombosis. Patients in the ST group had a higher prevalence of comorbid conditions such as diabetes mellitus (46 vs. 24%, p ¼ 0.0009), hypertension (72 vs. 52%, p ¼ 0.0071), dyslipidemia (67 vs. 40%, p ¼ 0.0003), prior MI (32 vs. 6%, p 0.0001), and prior coronary artery bypass grafting (12 vs. 2%, p ¼ 0.0004). Three-vessel disease was more common in patients with ST than in the non-ST group (28 vs. 14%, p ¼ 0.0106) (►Table 1).
The ejection fraction was lower in patients with ST (37 AE 5%) compared with the non-ST group (44 AE 16%) (p ¼ 0.0011). Median peak creatine phosphokinase (CPK) was higher in the ST group than in the non-ST group; however, this was not statistically significant (2,319 vs. 1,508 IU/L, p ¼ 0.084). A higher post-PCI TIMI 3 flow was seen in the ST group compared with the non-ST group (84 vs. 79%, p ¼ 0.003). In-hospital mortality was low in general, and did not differ between the two groups (2 vs. 4%, p ¼ 0.7082) (►Table 1).
ST was seen most commonly as "very late" (56%) ST followed by "subacute" (25%) ST. Eleven patients with ST (19%) had bare metal stents, 19 patients (34%) had firstgeneration DES, and 23 patients (40%) had second-generation DES. Stent type was unknown in 4 patients (7%). Of the patients presenting with ST, 24 patients (42%) were taking DAPT at the time of the event. Although 82% of patients who presented with early ST were on DAPT, only 22% of patients with very late ST were on DAPT (►Fig. 1). Premature termination of DAPT was seen in seven patients (12%) due to noncompliance or social circumstances. In 7 patients (12%), DAPT was held by a physician appropriately prior to a surgery or a procedure.
Discussion
Although ST is an uncommon complication after PCI, it carries significant morbidity and mortality. Patients with ST generally present with large STEMI, and PCI of ST has been shown previously to have a lower successful reperfusion rate. 7 ST accounted for 3 to 8.5% of cases of STEMI in previous registries, [8] [9] [10] and recent data have shown that the relative prevalence is increasing. 8 In our cohort of patients with STEMI, ST was seen in 11% of cases. Patients with STEMI due to ST were reported to have mortality ranging from 11 to 42%, with higher in-hospital mortality than those with a STEMI due to a native coronary lesion. 7 Recent data suggest lower mortality than previously reported, with early ST having higher in-hospital mortality than late or very late ST (7.9, 3.8, and 3.6%, respectively, p < 0.001). 11, 12 Our in-hospital mortality in patients who presented with STEMI due to ST was 2%.
Prospective studies have shown that most cases of ST occur early, within 30 days of stent placement. In the Dutch Stent Thrombosis Registry of 21,009 patients, 73% of ST occurred within 30 days. 13 However, in large registries of patients with STEMI, the most common presentation of ST was very late ST, 8, 14 likely due to the increasing number of patients at risk for very late ST. In our cohort of patients, more than 50% of patients presented with very late ST. Although first-generation DES showed increased risk of very late ST, secondgeneration DES 5, 15 have been shown to reduce the incidence of ST. However, 40% of patients in our cohort who presented with ST had ST of second-generation DES. This may be reflective of our current standard practice with increasing use of second-generation stents. The mechanism of ST is thought to be multifactorial including factors related to patients, stents, lesions, and procedures. Early cessation of DAPT, undersizing of the coronary stent, malignancy, and intermediate lesion proximal to the culprit lesion were reported to be predictors of ST.
13
Although early ST is more likely associated with procedural factors, late ST is thought to be associated with delayed endothelial coverage, persistent fibrin deposition, and ongoing vessel inflammation. International registries of 492 cases of late/very late ST could not identify strong predictors for late/very late ST. 16 Recently, neoatherosclerosis has been suggested as the mechanism of very late ST. Optimal coherence tomography images of 33 patients with very late ST showed that the neointimal rupture and thrombosis were the most common mechanisms of definite very late ST.
17
The duration of DAPT post-PCI remains an on-going debate. The current ACC guidelines state a class IB recommendation to continue DAPT for 12 months following stent placement. 18 A recently published DAPT study has shown significantly reduced risk of ST with 30 months of DAPT poststent placement. 19 In our population, 42% of patients were taking DAPT at the time of the event, and only 22% of patients who presented with very late ST were taking DAPT. Noncompliance was seen in 12% of patients, but 12% of patients were told by their physician to hold DAPT for a procedure, which represents a challenge to our daily practice. The large PARIS registry studied the pattern of DAPT cessation, and concluded DAPT disruption (premature discontinuation), especially in the first 7 days, was strongly associated with increased risk of ST.
20
Our study has several limitations including those usually associated with retrospective observational studies. Our small sample size does not allow us to evaluate clinical outcomes, and long-term follow-up was not routinely available. As for the procedure, intravascular ultrasound was not routinely used, which could have added more value to the data regarding stent malapposition and stent expansion, which are thought to be predictors of ST.
Conclusion
In our real-world practice, ST was the cause of STEMI in 11% of patients. ST can be seen in a variety of clinical settings and the most common presentation was very late ST. Moreover, we observed that 40% of ST occurred in second-generation DES. With an increasing number of patients at risk, ST will continue to be a challenge facing contemporary practice. Disclosure None. Fig. 1 The timing of stent thrombosis and the number of patients who were on DAPT; 100% of acute, 79% of subacute, 50% of late, and 22% of very late stent thromboses were taking DAPT. DAPT, dual antiplatelet therapy.
